India’s Pharma Industry Faces Fresh Challenges After Trump’s Drug Order

In a significant shift that could disrupt global pharmaceutical pricing, US President Donald Trump has announced a “Most Favoured Nation” (MFN) executive order aiming to ensure that Americans pay no more for prescription drugs than the lowest price paid globally. This move is expected to benefit American consumers in the short term but may lead to rising prices in low-cost markets like India and pressure on its domestic pharmaceutical policy.

Why in News?

The MFN policy announced by Trump on May 12, 2025, could lead to a recalibration of drug prices worldwide. As global pharma companies aim to align drug pricing across countries, India—known for its affordable generics—could be pushed to hike prices. The development has already caused turmoil in Indian pharmaceutical stocks over margin concerns.

What is the MFN Policy?

• Under the MFN policy, the US will pay no more than the lowest price for a drug anywhere in the world.
• It aims to reduce prescription drug prices by 30–80% in the US.
• Prices in other countries, particularly those where drugs are cheap, may rise due to global parity efforts.

Why It Matters

• It seeks fairness for American consumers, who often pay 5–10 times more for the same drug.
• US pharmaceutical firms are under pressure to reduce domestic prices, affecting their global pricing strategies.

Implications for India

• India is a leading generic drug supplier for the US and UK.
• Global pharma firms may push India to raise drug prices to avoid setting low benchmarks under MFN.
• India has resisted “TRIPS-plus” demands (e.g., patent linkage, data exclusivity) via Free Trade Agreements (FTAs).
• India’s drug laws currently comply with WTO’s TRIPS, protecting access to affordable medicines.

Industry Response

• Indian pharma generic exporters may not suffer directly but distributors and patent holders could see squeezed margins.
• In the US market, 79% of drugs are patented, while generics cover 21%.
• Executives argue that supply chain profiteering is a key price inflation factor in the US, not drug manufacturing costs.

Market Reaction

• Pharma stocks in India declined sharply over concerns about reduced profit margins.
• Concerns remain over global pharma lobbying efforts that may seek to reshape Indian drug pricing through trade negotiations.

Summary/Static	Details
Why in the news?	India’s Pharma Industry Faces Fresh Challenges After Trump’s Drug Order
Policy Introduced	Most Favoured Nation (MFN) Pricing Order by US President Donald Trump
Goal Align	US drug prices with the lowest global prices
Potential Impact on India	Pressure to increase drug prices and alter IP laws
Beneficiaries	US consumers (short-term)
Risk Areas	Pharma company margins, especially distributors; potential FTAs impact
Industry Opinion	(India) Cost burden lies more on supply chain than manufacturers